Transforming growth factor β and Ras/MEK/ERK signaling regulate the expression level of a novel tumor suppressor lefty

Pancreas

Volumn 41, Issue 5, 2012, Pages 745-752

  Miyata, Naoteru ^a   Azuma, Toshifumi ^b   Hozawa, Shigenari ^a   Higuchi, Hajime ^a   Yokoyama, Akiko ^b   Kabashima, Ayano ^a   Igarashi, Toru ^a   Saeki, Keita ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

Author keywords

C Jun N terminal kinase; Extracellular signal regulated kinase; P38 map kinase; Phosphoinositide 3 kinase; Smad dependent pathway; Small interfering RNA

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; K RAS PROTEIN; LEFT RIGHT DETERMINATION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN NODAL; RAS PROTEIN; SMAD4 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; UPREGULATION;

BUTADIENES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMONES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEFT-RIGHT DETERMINATION FACTORS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MORPHOLINES; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PYRAZOLES; PYRIDAZINES; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84863717210     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823b66d3     Document Type: Article

References (60)

1. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet. 2001;29:117-129.
2. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol. 2001;186:153-168.
3. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100:8621-8623.
4. Markowitz S, Wang J, Vogelstein B, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336-1338.
5. Hahn SA, Hoque AT, Kern SE, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996;56:490-494.
6. Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 1999;18:5363-5372.
7. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103:295-309.
8. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506-520.
9. Eppert K, Scherer SW, Attisano L, et al. MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell. 1996;86:543-552.
10. ras by transforming growth factor beta in epithelial cells. J Biol Chem. 1992;267:5029-5031.
11. Mulder KM. Role of Ras and MAPKs in TGFbeta signaling. Cytokine Growth Factor Rev. 2000;11:23-35.
12. MAPK in proliferating cultures of epithelial cells. J Biol Chem. 1995;270:7117-7124.
13. Sano Y, Harada J, Ishii S, et al. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-beta signaling. J Biol Chem. 1999;274:8949-8957.
14. Hanafusa H, Ninomiya-Tsuji J, Nishida E, et al. Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem. 1999;274:27161-27167.
15. Hocevar BA, Brown TL, Howe PH, et al. TGF-beta induces fibronectin synthesis through a c-Jun. N-terminal kinase-dependent, Smad4-independent pathway. EMBO J. 1999;18:1345-1356.
16. Bhowmick NA, Ghiassi M, Moses HL, et al. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell. 2001;12:27-36.
17. Zhang YE. Non-Smad pathways in TGF-beta signaling. Cell Res. 2009;19:128-139.
18. Meno C, Saijoh Y, Hamada H, et al. Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos. Nature. 1996;381:151-155.
19. Meno C, Ito Y, Hamada H, et al. Two closely-related left-right asymmetrically expressed genes, lefty-1 and lefty-2: their distinct expression domains, chromosomal linkage and direct neuralizing activity in Xenopus embryos. Genes Cells. 1997;2:513-524.
20. Schier AF. Nodal signaling in vertebrate development. Annu Rev Cell Dev Biol. 2003;19:589-621.
21. Chen C, Shen MM. Two modes by which Lefty proteins inhibit nodal signaling. Curr Biol. 2004;14:618-624.
22. Cheng SK, Olale F, Schier AF, et al. Lefty blocks a subset of TGFbeta signals by antagonizing EGF-CFC coreceptors. PLoS Biol. 2004;2:E30.
23. Sakuma R, Ohnishi Yi Y, Hamada H, et al. Inhibition of Nodal signalling by Lefty mediated through interaction with common receptors and efficient diffusion. Genes Cells. 2002;7:401-412.
24. Branford WW, Yost HJ. Lefty-dependent inhibition of Nodal-and Wnt-responsive organizer gene expression is essential for normal gastrulation. Curr Biol. 2002;12:2136-2141.
25. Chen Y, Schier AF. Lefty proteins are long-range inhibitors of squint-mediated nodal signaling. Curr Biol. 2002;12:2124-2128.
26. Yashiro K, Saijoh Y, Hamada H, et al. Distinct transcriptional regulation and phylogenetic divergence of human LEFTY genes. Genes Cells. 2000;5:343-357.
27. Tabibzadeh S, Kothapalli R, Buyuksal I. Distinct tumor specific expression of TGF-β4 (ebaf), a novel human gene of the TGF-beta superfamily. Front Biosci. 1997;2:a18-a25.
28. Ulloa L, Tabibzadeh S. Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor. J Biol Chem. 2001;276:21397-21404.
29. Topczewska JM, Postovit LM, Hendrix MJ, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med. 2006;12:925-932.
30. Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777) Yinduced inhibition of STAT3 (Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res. 2005;65:2861-2871.
31. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3:807-821.
32. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-584.
33. Moustakas A, Heldin CH. Non-Smad TGF-beta signals. J Cell Sci. 2005;118:3573-3584.
34. Feng XH, Derynck R. Specificity and versatility in TGF-beta signaling through Smads. Annu Rev Cell Dev Biol. 2005;21:659-693.
35. Akhurst RJ, Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 2001;11:S44-S51.
36. Arrick BA, Lopez AR, Derynck R, et al. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol. 1992;118:715-726.
37. Roberts AB, Sporn MB, Kehrl JH, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
38. Wang D, Zhou GH, Brattain MG, et al. Autocrine transforming growth factor beta 1 modulates the expression of integrin alpha 5 beta 1 in human colon carcinoma FET cells. J Biol Chem. 1995;270:14154-14159.
39. Torre-Amione G, Beauchamp RD, Rowley DA, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance. Proc Natl Acad Sci U S A. 1990;87:1486-1490.
40. Cheng N, Bhowmick NA, Moses HL, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alphaY, MSP-and HGF-mediated signaling networks. Oncogene. 2005;24:5053-5068.
41. Bian Y, Terse A, Kulkarni AB, et al. Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway. Cancer Res. 2009;69:5918-5926.
42. Northey JJ, Chmielecki J, Siegel PM, et al. Signaling through ShcA is required for transforming growth factor betaY and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol. 2008;28:3162-3176.
43. Ragazzon B, Cazabat L, Bertherat J, et al. Inactivation of the Carney complex gene 1 (protein kinase A regulatory subunit 1A) inhibits SMAD3 expression and TGF beta-stimulated apoptosis in adrenocortical cells. Cancer Res. 2009;69:7278-7284.
44. Shi J, Wang DM, Song JG, et al. Insulin receptor substrate-1 suppresses transforming growth factor-beta1-mediated epithelial-mesenchymal transition. Cancer Res. 2009;69:7180-7187.
45. Uttamsingh S, Chu TT, Wang LH, et al. Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene. 2008;27:2626-2634.
46. Hruban RH, Adsay NV. Molecular classification of neoplasms of the pancreas. Hum Pathol. 2009;40:612-623.
47. Hahn SA, Schutte M, Kern SE, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
48. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597-641.
49. Sporn MB, Roberts AB. The transforming growth factor-betas: past, present, and future. Ann N Y Acad Sci. 1990;593:1-6.
50. Alexandrow MG, Moses HL. Transforming growth factor beta 1 inhibits mouse keratinocytes late in G1 independent of effects on gene transcription. Cancer Res. 1995;55:3928-3932.
51. Schwarz LC, Gingras MC, Wright JA, et al. Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts. Cancer Res. 1988;48:6999-7003.
52. Houck KA, Michalopoulos GK, Strom SC. Introduction of a Ha-ras oncogene into rat liver epithelial cells and parenchymal hepatocytes confers resistance to the growth inhibitory effects of TGF-beta. Oncogene. 1989;4:19-25.
53. Kretzschmar M, Doody J, Massague J, et al. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras. Genes Dev. 1999;13:804-816.
54. Postovit LM, Margaryan NV, Hendrix MJ, et al. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci U S A. 2008;105:4329-4334.
55. Minchiotti G. Nodal-dependant Cripto signaling in ES cells: from stem cells to tumor biology. Oncogene. 2005;24:5668-5675.
56. Zhang L, Wang W, Xia Y, et al. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J. 2003;22:4443-4454.
57. Perlman R, Schiemann WP, Weinberg RA, et al. TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol. 2001;3:708-714.
58. Chiu C, Maddock DA, Wan Y, et al. TGF-beta-induced p38 activation is mediated by Rac1-regulated generation of reactive oxygen species in cultured human keratinocytes. Int J Mol Med. 2001;8:251-255.
59. Yi JY, Shin I, Arteaga CL. Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. J Biol Chem. 2005;280:10870-10876.
60. Bitzer M, von Gersdorff G, Bottinger EP, et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev. 2000;14:187-197.